Avacopan for anti‑neutrophil cytoplasmic antibody‑associated vasculitis: a meta‑analysis of efficacy and safety
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
ObjectiveTo systematically evaluate the efficacy and safety of avacopan in patients with anti‑neutrophil cytoplasmic antibody‑associated vasculitis(AAV).MethodsWe performed a comprehensive literature search of Embase, PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang, and VIP from database inception to June 2025 for randomized controlled trials (RCTs) and cohort studies assessing avacopan in AAV. Data were pooled using RevMan 5.4.ResultsTen studies (3 RCTs and 7 cohort studies) comprising 727 patients were included. In RCTs, avacopan did not significantly affect overall remission rate compared with control (RR=1.03; 95%CI:0.90-1.18; P=0.69), but it significantly improved sustained remission rate (RR=1.22; 95%CI:1.02⁃1.45; P=0.03). Cohort studies showed a lower relapse rate with avacopan versus control (RR=0.49; 95%CI:0.30-0.79; P=0.004). Single‑arm pooled analyses indicated high event rates for remission (88%; 95%CI:0.82-0.92) and sustained remission (87%; 95%CI:0.78-0.93), with a low pooled relapse proportion (7%; 95%CI:0.04-0.12). Renal outcomes favored avacopan: RCTs showed a small but statistically significant improvement in eGFR [mL·min-1·(1.73 m2)-1] change from baseline to endpoint (MD=2.76; 95%CI:0.21-5.30; P=0.03). Real‑world cohort data demonstrated clinically meaningful eGFR gains at 6 months (MD=9.40; 95%CI:0.44-18.37; P=0.04) and 12 months (MD=13.88; 95%CI:8.47-19.28; P
Fields of Study & Subjects
Vasculitis and related conditions
Complement system in diseases
Systemic Lupus Erythematosus Research
Publication details
- Journal / source
- DOAJ (DOAJ: Directory of Open Access Journals)
- Publication date
- 1 March 2026
- Language
- ZH